Stereotaxis, Inc.

NYSE American STXS

Stereotaxis, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 56.14%

Stereotaxis, Inc. Gross Profit Margin is 56.14% for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.82% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Stereotaxis, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 55.69%, a -19.46% change year over year.
  • Stereotaxis, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 69.14%, a 3.24% change year over year.
  • Stereotaxis, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 66.97%, a -5.36% change year over year.
  • Stereotaxis, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 70.76%, a -11.68% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
NYSE American: STXS

Stereotaxis, Inc.

CEO Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
IPO Date Aug. 12, 2004
Location United States
Headquarters 710 North Tucker Boulevard
Employees 122
Sector Technology
Industries
Description

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

Similar companies

EDAP

EDAP TMS S.A.

USD 2.02

-2.42%

ATRC

AtriCure, Inc.

USD 34.69

0.87%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

ARAY

Accuray Incorporated

USD 2.20

-1.79%

StockViz Staff

January 15, 2025

Any question? Send us an email